Promoting Life Sciences Research Centered on the Gut Microbiota
First written in FY2016. 17 of 30 entries say "Restated". Latest entry: FY2026.
4 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Total R&D expenses for the consolidated fiscal year were ¥9,733 million, and an overview of R&D activities related to segment information is as follows.」
The company recorded R&D expenses of ¥9,733 million and published research results on upper respiratory tract infections, anemia, the intestinal environment and aflatoxin accumulation associated with Shirota strain in academic journals. - 2026-05-12AdvancedFinancial Results Presentation
「R&D expenses 9,398 103.3 9,733 103.6 10,363 106.5」
R&D expenses increased from ¥9,398 million in the previous fiscal year to ¥9,733 million, with ¥10,363 million forecast for the fiscal year ending March 2027. - FY2026-H1AdvancedAnnual report
「Regarding the R&D Center, we established Yakult European R&D Center B.V. in the Netherlands in September, with the aim of building a global R&D structure to address regulations and diverse consumer needs in each country.」
While there were no material changes in the R&D activities themselves, the company established a base for its global R&D structure in the Netherlands to address regulations and consumer needs in each country. - FY2025AdvancedAnnual report
「Total R&D expenses for the consolidated fiscal year were ¥9,398 million, and an overview of R&D activities related to segment information is as follows.」
The company recorded R&D expenses of ¥9,398 million and published research results on lactic acid bacteria and the gut microbiome, the mechanism of hay fever, and the antibacterial and antiviral effects of fucoidan in academic journals. It continues to pursue applications in medical microbiome products and novel functional ingredients. - FY2025-H1RestatedAnnual report
「Total R&D expenses for the current interim consolidated fiscal period were ¥4,627 million. There were no material changes in the status of the Group's R&D activities during the current interim consolidated fiscal period.」
The company recorded R&D expenses of ¥4,627 million and stated that there were no material changes in the status of its R&D activities. - FY2024AdvancedAnnual report
「Total R&D expenses for the consolidated fiscal year were ¥9,095 million, and an overview of R&D activities related to segment information is as follows.」
The company recorded R&D expenses of ¥9,095 million and published results of joint research on sleep, cow's milk allergy and gut microbiota in academic journals. It continues research into the gut microbiome, next-generation probiotics and novel functional ingredients. - FY2024-Q3RestatedAnnual report
「Total R&D expenses for the cumulative third quarter of the current consolidated fiscal year were ¥6,448 million. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter of the current consolidated fiscal year.」
The company recorded R&D expenses of ¥6,448 million for the cumulative third quarter and stated that there were no material changes in the status of its R&D activities. - FY2024-Q2RestatedAnnual report
「Total R&D expenses for the cumulative second quarter of the current consolidated fiscal year were ¥4,311 million. There were no material changes in the status of the Group's R&D activities during the cumulative second quarter of the current consolidated fiscal year.」
The company recorded R&D expenses of ¥4,311 million and stated that there were no material changes in the status of its R&D activities. - FY2023AdvancedAnnual report
「Total R&D expenses for the consolidated fiscal year were ¥9,381 million, and an overview of R&D activities related to segment information is as follows.」
The company recorded R&D expenses of ¥9,381 million and published results of joint research on effects on immune cells and preoperative chemotherapy for esophageal cancer patients in academic journals. - FY2023-Q3RestatedAnnual report
「Total R&D expenses for the cumulative third quarter of the current consolidated fiscal year were ¥6,606 million. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter of the current consolidated fiscal year.」
The company recorded R&D expenses of ¥6,606 million for the cumulative third quarter and stated that there were no material changes in the status of its R&D activities. - FY2023-Q2RestatedAnnual report
「Total R&D expenses for the cumulative second quarter of the current consolidated fiscal year were ¥4,388 million. There were no material changes in the status of the Group's R&D activities during the cumulative second quarter of the current consolidated fiscal year.」
The company recorded R&D expenses of ¥4,388 million for the cumulative second quarter and stated that there were no material changes in the status of its R&D activities. - FY2022AdvancedAnnual report
「Total R&D expenses for the consolidated fiscal year were ¥8,655 million, and an overview of R&D activities related to segment information is as follows.」
The company published multiple results of joint research on the gut microbiome and health in academic journals, examining the effects of probiotics and synbiotics on depressive symptoms, gut microbiota stabilization and preoperative chemotherapy for esophageal cancer patients. - FY2022-Q3RestatedAnnual report
「Total R&D expenses for the cumulative third quarter of the current consolidated fiscal year were ¥6,327 million. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter of the current consolidated fiscal year.」
The company recorded R&D expenses of ¥6,327 million and stated that there were no material changes in the status of its R&D activities. - FY2022-Q2RestatedAnnual report
「Total R&D expenses for the cumulative second quarter of the current consolidated fiscal year were ¥4,299 million. There were no material changes in the status of the Group's R&D activities during the cumulative second quarter of the current consolidated fiscal year.」
The company recorded R&D expenses of ¥4,299 million but stated that there were no material changes in the status of its R&D activities. - FY2022-Q1RestatedAnnual report
「Total R&D expenses for the cumulative first quarter of the current consolidated fiscal year were ¥2,111 million. There were no material changes in the status of the Group's R&D activities during the cumulative first quarter of the current consolidated fiscal year.」
The company recorded R&D expenses of ¥2,111 million and stated that there were no material changes in the status of its R&D activities. - FY2021AdvancedAnnual report
「Total R&D expenses for the consolidated fiscal year were ¥8,487 million, and an overview of R&D activities related to segment information is as follows.」
In gut microbiome research, the company published results of joint research on gut microbiota dynamics, a drinking trial involving approximately 1,000 Vietnamese children, gut microbiota development in infants, hay fever and postoperative complications of esophageal cancer in academic journals. It continues to focus on next-generation probiotics and novel functional ingredients. - FY2021-Q3RestatedAnnual report
「Total R&D expenses for the cumulative third quarter of the current consolidated fiscal year were ¥6,108 million. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter of the current consolidated fiscal year.」
The company recorded R&D expenses of ¥6,108 million but stated that there were no material changes in the status of its R&D activities. - FY2021-Q2RestatedAnnual report
「Total R&D expenses for the cumulative second quarter of the current consolidated fiscal year were ¥4,069 million. There were no material changes in the status of the Group's R&D activities during the cumulative second quarter of the current consolidated fiscal year.」
The company recorded R&D expenses of ¥4,069 million but stated that there were no material changes in the status of its R&D activities. - FY2021-Q1RestatedAnnual report
「Total R&D expenses for the cumulative first quarter of the current consolidated fiscal year were ¥1,983 million. There were no material changes in the status of the Group's R&D activities during the cumulative first quarter of the current consolidated fiscal year.」
The company recorded R&D expenses of ¥1,983 million for the first quarter and stated that there were no material changes in the status of its R&D activities. - FY2020AdvancedAnnual report
「Going forward, we will promote gut microbiome research based on cutting-edge biotechnology and work to verify and elucidate the health-maintaining and health-promoting functions of probiotics. We will also focus our R&D efforts on next-generation probiotics targeting the prevention of lifestyle-related diseases and on novel functional ingredients.」
The company recorded R&D expenses of ¥8,968 million and published specific results of joint research with universities and medical institutions on constipation, fever, hay fever and low-birth-weight infants in academic journals. It also explicitly indicated a focus on next-generation probiotics and novel functional ingredients. - FY2020-Q3RestatedAnnual report
「Total R&D expenses for the cumulative third quarter of the current consolidated fiscal year were ¥6,408 million. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter of the current consolidated fiscal year.」
The company recorded R&D expenses of ¥6,408 million and stated that there were no material changes in the status of its R&D activities. - FY2020-Q2RestatedAnnual report
「Total R&D expenses for the cumulative second quarter of the current consolidated fiscal year were ¥4,343 million. There were no material changes in the status of the Group's R&D activities during the cumulative second quarter of the current consolidated fiscal year.」
The company recorded R&D expenses of ¥4,343 million for the cumulative second quarter and stated that there were no material changes in the status of its R&D activities. - FY2020-Q1RestatedAnnual report
「Total R&D expenses for the cumulative first quarter of the current consolidated fiscal year were ¥2,110 million. There were no material changes in the status of the Group's R&D activities during the cumulative first quarter of the current consolidated fiscal year.」
The company recorded R&D expenses of ¥2,110 million and stated that there were no material changes in the status of its R&D activities. - FY2019AdvancedAnnual report
「The results were all equivalent to the control samples stored on the ground, confirming that probiotic functionality was maintained in the space environment.」
The company recorded R&D expenses of ¥10,563 million and published results of joint research with JAXA, universities and medical institutions in academic journals. It continues research into the gut microbiome, next-generation probiotics and novel functional ingredients. - FY2019-Q3RestatedAnnual report
「Total R&D expenses for the cumulative third quarter of the current consolidated fiscal year were ¥7,984 million. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter of the current consolidated fiscal year.」
The company recorded R&D expenses of ¥7,984 million but stated that there were no material changes in the status of its R&D activities. - FY2019-Q2RestatedAnnual report
「Total R&D expenses for the cumulative second quarter of the current consolidated fiscal year were ¥5,671 million. There were no material changes in the status of the Group's R&D activities during the cumulative second quarter of the current consolidated fiscal year.」
The company recorded R&D expenses of ¥5,671 million and stated that there were no material changes in the status of its R&D activities. - FY2019-Q1RestatedAnnual report
「Total R&D expenses for the cumulative first quarter of the current consolidated fiscal year were ¥3,297 million. There were no material changes in the status of the Group's R&D activities during the cumulative first quarter of the current consolidated fiscal year.」
The company recorded R&D expenses of ¥3,297 million and stated that there were no material changes in the status of its R&D activities. - FY2018AdvancedAnnual report
「Total R&D expenses for the consolidated fiscal year were ¥10,207 million, and an overview of R&D activities related to segment information is as follows.」
The company published multiple results of joint research with universities and medical institutions on the relationship between the gut microbiome and health in academic journals, investing ¥10,207 million in R&D. It has indicated a policy of focusing on research into next-generation probiotics and novel functional ingredients. - FY2017AdvancedAnnual report
「As a result, in April last year we obtained ISO/IEC 17025 accreditation for the volatile organic compounds (VOC) test in tap water, one of the items in our raw-material water analysis.」
The company has continued basic and applied research centered on the gut microbiome and reported concrete progress in its research and analytical infrastructure, including obtaining ISO/IEC 17025 accreditation for analytical testing. - FY2016First statedAnnual report
「We aim to fulfill our corporate philosophy of contributing to healthy and enjoyable lives for people around the world by pursuing life sciences research focused on the role in humans of microorganisms that make up the gut microbiota, or gut microbiome.」
The company has presented an integrated R&D policy encompassing basic research, applications in foods, pharmaceuticals and cosmetics, and safety and environmental measures.